(NYSE: BDX) Becton Dickinson & Co's forecast annual revenue growth rate of 1.38% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 7.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.56%.
Becton Dickinson & Co's revenue in 2026 is $20,840,000,000.On average, 18 Wall Street analysts forecast BDX's revenue for 2027 to be $5,429,758,471,200, with the lowest BDX revenue forecast at $5,229,009,399,600, and the highest BDX revenue forecast at $5,783,316,537,600. On average, 15 Wall Street analysts forecast BDX's revenue for 2028 to be $5,645,761,203,600, with the lowest BDX revenue forecast at $5,408,239,914,000, and the highest BDX revenue forecast at $6,076,949,508,000.
In 2029, BDX is forecast to generate $5,969,629,108,800 in revenue, with the lowest revenue forecast at $5,630,235,156,000 and the highest revenue forecast at $6,379,571,242,800.